TVRD Investor Alert: Faruqi & Faruqi Launches Probe Into Tvardi Therapeutics Losses

Faruqi & Faruqi, LLP — a major U.S. securities‑litigation firm — announced on Nov. 30, 2025 that it is investigating potential claims on behalf of investors who suffered heavy losses in Tvardi Therapeutics, Inc. (NASDAQ: TVRD). The firm notes that on Oct. 13, 2025, shares of Tvardi collapsed by over 80% following the release of disappointing preliminary data from the Phase 2 REVERT clinical trial of its drug candidate TTI-101 for idiopathic pulmonary fibrosis. The study failed to meet its goals: safety and exploratory efficacy measures — including changes in Forced Vital Capacity (FVC) — did not show sufficient benefit. Investors who incurred “significant losses” in Tvardi stock or options are encouraged to contact senior partner James (Josh) Wilson at 877‑247‑4292 or 212‑983‑9330 (Ext. 1310) to discuss potential legal rights and next steps. Faruqi & Faruqi highlights its track record — the firm has recovered hundreds of millions of dollars for investors since its founding in 1995 — but cautions that past results do not guarantee a successful outcome for any given case. #TvardiTherapeutics #InvestorAlert #BiotechDrop #ShareholderRights #SlimScan #GrowthStocks #CANSLIM